Trial Profile
A Phase 2, Randomized, Open-Label Study of Bosutinib Administered in Combination With Exemestane Versus Exemestane Alone as Second Line Therapy in Postmenopausal Women With Locally Advanced or Metastatic ER+/PgR+/ErbB2- Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Bosutinib
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Pfizer
- 05 Oct 2021 This trial has been completed in Spain and France (End Date: 31 May 2010), according to European Clinical Trials Database record.
- 15 Feb 2012 Additional locations added as reported by Clinical Trials Registry - India record.
- 29 Aug 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.